衍生集團(06893.HK)擬攜手紅力同源生物科技(威海)成立彭祖衍生館(廣東)品牌管理公司
格隆匯12月29日丨衍生集團(06893.HK)公吿,於2021年12月29日,衍生健康醫藥(廣東)有限公司("衍生廣東",公司全資附屬公司)與紅力同源生物科技(威海)有限公司訂立合作協議以成立新公司彭祖衍生館(廣東)品牌管理有限公司。
根據合作協議,品牌管理公司將於中華人民共和國開設名為彭祖衍生館的連鎖店,獨家銷售由衍生廣東供應的產品。
董事會認為,透過成立品牌管理公司並於中國開設廣泛覆蓋的連鎖店,本集團可進一步鞏固產品分銷渠道,並抓握中國迅速發展的保健市場帶來的龐大商機。董事會認為,合作協議乃按一般商業條款訂立,其條款屬公平合理,而其項下擬進行的交易符合本公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.